PMID- 34531798
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210918
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Electronic)
IS  - 1664-1078 (Linking)
VI  - 12
DP  - 2021
TI  - Impulsivity and Its Relationship With Lisdexamfetamine Dimesylate Treatment in 
      Binge Eating Disorder.
PG  - 716010
LID - 10.3389/fpsyg.2021.716010 [doi]
LID - 716010
AB  - High trait impulsivity is thought to contribute to the sense of loss of control 
      over eating and impulses to binge eat experienced by those with binge eating 
      disorder (BED). Lisdexamfetamine dimesylate (LDX), a drug approved for treatment 
      of moderate to severe BED, has been shown to decrease impulsive features of BED. 
      However, the relationship between LDX-related reductions of binge eating (BE) 
      episodes and impulsivity has not yet been explored. Forty-one adults aged 
      18-40years with moderate to severe BED completed questionnaires and tasks 
      assessing impulsivity at baseline and after 8weeks of 50-70mg of LDX. Twenty 
      age-matched healthy controls were also assessed at two timepoints for normative 
      comparison. Data were analysed using linear mixed models. BED participants 
      exhibited increased self-reported motor, non-planning, cognitive and food-related 
      impulsivity relative to controls but no differences in objective task-based 
      measures of impulsivity. Food-related and non-planning impulsivity was 
      significantly reduced by LDX, but not to normative levels. Individuals with 
      higher baseline levels of motor and non-planning impulsivity, and loss of control 
      over eating scores experienced the greatest reduction in BE frequency after 
      8weeks of LDX. Further, there were significant associations between the degree to 
      which subjective loss of control over eating, non-planning impulsivity and BE 
      frequency reduced after 8weeks of LDX. These data suggest that specific 
      subjective measures of impulsivity may be able to predict who will have the 
      greatest benefit from LDX treatment and that reductions in BE frequency may be 
      moderated by concurrent reductions in non-planning impulsivity.
CI  - Copyright (c) 2021 Griffiths, Aparicio, Braund, Yang, Harvie, Harris, Hay, Touyz 
      and Kohn.
FAU - Griffiths, Kristi R
AU  - Griffiths KR
AD  - Brain Dynamics Centre, Westmead Institute for Medical Research, University of 
      Sydney, Westmead, NSW, Australia.
FAU - Aparicio, Leonor
AU  - Aparicio L
AD  - Brain Dynamics Centre, Westmead Institute for Medical Research, University of 
      Sydney, Westmead, NSW, Australia.
AD  - Faculty of Medicine, University of Porto, Porto, Portugal.
FAU - Braund, Taylor A
AU  - Braund TA
AD  - Brain Dynamics Centre, Westmead Institute for Medical Research, University of 
      Sydney, Westmead, NSW, Australia.
AD  - BlackDog Institute, Sydney, NSW, Australia.
AD  - Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
FAU - Yang, Jenny
AU  - Yang J
AD  - Brain Dynamics Centre, Westmead Institute for Medical Research, University of 
      Sydney, Westmead, NSW, Australia.
FAU - Harvie, Grace
AU  - Harvie G
AD  - Brain Dynamics Centre, Westmead Institute for Medical Research, University of 
      Sydney, Westmead, NSW, Australia.
FAU - Harris, Anthony
AU  - Harris A
AD  - Brain Dynamics Centre, Westmead Institute for Medical Research, University of 
      Sydney, Westmead, NSW, Australia.
AD  - Discipline of Psychiatry, Faculty of Medicine and Health, The University of 
      Sydney, Sydney, NSW, Australia.
FAU - Hay, Phillipa J
AU  - Hay PJ
AD  - School of Medicine, Translational Health Research Institute, Western Sydney 
      University, Sydney, NSW, Australia.
FAU - Touyz, Stephen
AU  - Touyz S
AD  - Clinical Psychology Unit, School of Psychology, University of Sydney, Sydney, 
      NSW, Australia.
AD  - InsideOut Institute, Charles Perkins Centre, University of Sydney, Sydney, NSW, 
      Australia.
FAU - Kohn, Michael R
AU  - Kohn MR
AD  - Centre for Research into Adolescents' Health (CRASH), University of Sydney, 
      Sydney, NSW, Australia.
AD  - Adolescent and Young Adult Medicine, Westmead Hospital, Sydney, NSW, Australia.
LA  - eng
PT  - Journal Article
DEP - 20210831
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC8439192
OTO - NOTNLM
OT  - binge eating disorder
OT  - clinical trial
OT  - drug therapy
OT  - impulsivity
OT  - lisdexamfetamine dimesylate
COIS- KG has been the recipient of honoraria from Shire (Takeda group of companies) for 
      public speaking engagements. PH receives/has received sessional fees and lecture 
      fees from the Australian Medical Council, Therapeutic Guidelines publication, and 
      HETI (New South Wales and the former NSW Institute of Psychiatry) and 
      royalties/honoraria from Hogrefe and Huber, McGraw Hill Education, and Blackwell 
      Scientific Publications, Biomed Central and PlosMedicine, and she has received 
      research grants from the NHMRC and ARC. She is Chair of the National Eating 
      Disorders Collaboration Steering Committee in Australia (2019-) and was Member of 
      the ICD-11 Working Group for Eating Disorders and was Chair Clinical Practice 
      Guidelines Project Working Group (Eating Disorders) of RANZCP (2012aeuro"2015). She 
      has prepared a report under contract for Takeda (formerly Shire) Pharmaceuticals 
      in regard to binge eating disorder (July 2017) and is a consultant to Takeda 
      Pharmaceuticals. All views in this paper are her own. ST has been the recipient 
      of honoraria from Shire (Takeda group of companies) for public speaking 
      engagements and commissioned reports. He has been the Chair of their Clinical 
      Advisory Group for binge eating disorder. He receives honoraria for books/book 
      chapters from McGraw Hill. Hogrefe and Huber and Taylor and Francis. He is the 
      co-director of the Inside Out Institute at the University of Sydney. ST is a 
      mental health consultant to BUPA. He is a member of the Department of Health 
      Technical Advisory Group for Eating Disorders (Commonwealth Government). MK has 
      been the recipient of honoraria from Shire (Takeda group of companies) for public 
      speaking engagements. LA, TB, JY, GH and AH have no potential conflicts of 
      interest to declare.
EDAT- 2021/09/18 06:00
MHDA- 2021/09/18 06:01
PMCR- 2021/08/31
CRDT- 2021/09/17 07:12
PHST- 2021/05/28 00:00 [received]
PHST- 2021/07/27 00:00 [accepted]
PHST- 2021/09/17 07:12 [entrez]
PHST- 2021/09/18 06:00 [pubmed]
PHST- 2021/09/18 06:01 [medline]
PHST- 2021/08/31 00:00 [pmc-release]
AID - 10.3389/fpsyg.2021.716010 [doi]
PST - epublish
SO  - Front Psychol. 2021 Aug 31;12:716010. doi: 10.3389/fpsyg.2021.716010. eCollection 
      2021.